Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Magazines
Fall Home Improvements 2024
Women
Home & Realty
Outdoor Guide
Premier Home Style Tour 2024
Spring Home & Garden Show 2025
Spring on the Road
Spring Wellness 2025
Canada Votes 2025
2024 Readers' Choice Awards
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
Ontario Votes
LAST CHANCE AUCTION
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Evolus, Inc. - Common Stock
(NQ:
EOLS
)
9.210
+0.070 (+0.77%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jun 30, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Evolus, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
Next >
Aesthetics Market Resilience: AbbVie Asserts Widely Used Botox Dominance Amidst Rising Competition
January 11, 2024
AbbVie Inc's (NYSE: ABBV) unwavering confidence in Botox's resilience within the aesthetics market with a commanding 68% market share remains steadfast. Despite a recent FDA petition addressing...
Via
Benzinga
Evolus Announces the Appointment of Nareg Sagherian to Vice President, Head of Global Investor Relations and Corporate Communications
January 04, 2024
From
Evolus
Via
Business Wire
Evolus Enters into Licensing Agreement with Symatese to Exclusively Distribute Next-Generation Dermal Fillers in Europe
December 20, 2023
From
Evolus
Via
Business Wire
Earnings Preview: Evolus
August 01, 2023
Via
Benzinga
5 Analysts Have This to Say About Evolus
July 28, 2023
Via
Benzinga
Botox And Similar Injections Have Associated Risks: Consumer Group Pushes for Stronger Warnings
December 12, 2023
Consumer advocacy group Public Citizen has filed a petition with the FDA, urging the agency to demand stronger warnings regarding the risk of a potentially fatal muscle-paralyzing disease linked to...
Via
Benzinga
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 08, 2023
From
Evolus
Via
Business Wire
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 10, 2023
From
Evolus
Via
Business Wire
Why Toast Shares Are Trading Lower By Around 17%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
November 08, 2023
Gainers Heart Test Laboratories, Inc. (NASDAQ: HSCS) shares climbed 96% to $0.2921 after falling over 7% on Tuesday.
Via
Benzinga
Roblox, Under Armour, GoPro, Nuvei And Other Big Stocks Moving Higher On Wednesday
November 08, 2023
U.S. stocks traded mostly lower, with the Nasdaq Composite falling around 20 points on Wednesday. Here are some big stocks recording gains in today’s session.
Via
Benzinga
Topics
Stocks
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
November 08, 2023
Via
Benzinga
Why American Public Education Shares Are Trading Higher By Around 21%; Here Are 20 Stocks Moving Premarket
November 08, 2023
Gainers Heart Test Laboratories, Inc. (NASDAQ: HSCS) shares surged 332% to $0.6455 in pre-market trading after falling over 7% on Tuesday.
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
November 07, 2023
Via
Benzinga
Evolus Reports Record Third Quarter 2023 Financial Results and Phase II Data for Extra-Strength 40U Formulation of Jeuveau®
November 07, 2023
From
Evolus
Via
Business Wire
“Extra-Strength” 40U Formulation of Jeuveau® Demonstrates Effects Lasting 26 Weeks in Phase II Data Presented at 2023 ASDS Annual Meeting
November 06, 2023
From
Evolus
Via
Business Wire
Evolus to Participate in November Investor Conferences
November 01, 2023
From
Evolus
Via
Business Wire
Evolus to Report Third Quarter 2023 Results
October 25, 2023
From
Evolus
Via
Business Wire
Final Phase 2 Data Evaluating 40U Dose of PrabotulinumtoxinA-xvfs to be Presented at 2023 ASDS Annual Meeting
October 25, 2023
From
Evolus
Via
Business Wire
7 Must-Own Small-Cap Stocks That Could Outperform the Market
October 08, 2023
If you’re ready to absorb significant risk for the chance of ridiculous upside, these small-cap stocks to buy may be just for you.
Via
InvestorPlace
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 29, 2023
From
Evolus
Via
Business Wire
7 Small-Cap Stocks Analysts Predict Will Double in 2024
September 13, 2023
While small-cap stocks to buy present exceptional risk, they also offer tremendous rewards for intrepid retail investors.
Via
InvestorPlace
Evolus to Participate in September Conferences
August 29, 2023
From
Evolus
Via
Business Wire
Evolus Announces Inducement Grants for New Chief Marketing Officer
August 23, 2023
From
Evolus
Via
Business Wire
Evolus Appoints Tomoko Yamagishi-Dressler as Chief Marketing Officer
August 21, 2023
From
Evolus
Via
Business Wire
Over $15M Bet On Impinj? Check Out These 4 Stocks Insiders Are Buying
August 16, 2023
Although U.S. stocks closed lower on Tuesday, there were a few notable insider trades.
Via
Benzinga
Stonegate Capital Partners Announces Publishing of a Thematic Report - Undervalued Growth Pharma Companies Amidst Healthcare Sector Decline
August 08, 2023
Dallas, Texas--(Newsfile Corp. - August 8, 2023) - Stonegate is pleased to announce the...
Via
Newsfile
Evolus Unveils New Branding for Flagship Product Jeuveau® to Reflect Growing and Evolving Consumers
August 08, 2023
From
Evolus
Via
Business Wire
Evolus Reports Second Quarter 2023 Results and Provides Business Update
August 02, 2023
From
Evolus
Via
Business Wire
12 Health Care Stocks Moving In Thursday's Intraday Session
July 27, 2023
Via
Benzinga
Why Willis Towers Watson Shares Are Trading Lower By 9%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
July 27, 2023
Gainers Femasys Inc. (NASDAQ: FEMY) gained 54% to $0.55. Femasys reported a notice of allowance for new U.S. patent application covering use of FemBloc for female permanent birth control.
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.